trending Market Intelligence /marketintelligence/en/news-insights/trending/-ZgWb1-r0ZpKRNbeOnPesQ2 content esgSubNav
In This List

Anthera Pharmaceuticals achieves full compliance with Nasdaq rules

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Anthera Pharmaceuticals achieves full compliance with Nasdaq rules

Anthera Pharmaceuticals Inc. said it achieved full compliance with all requirements for continued listing on the Nasdaq Capital Market.

The Hayward, Calif.-based biopharmaceutical company is now compliant with Nasdaq rules, including the $35 million market value of listed securities requirement.

Anthera's common stock was listed on the Nasdaq Capital Market on Jan. 26. The listing was subject to compliance with all of Nasdaq's requirements by May 14.

Anthera makes medicines for patients with unmet medical needs.